Literature DB >> 18290913

The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?

Rob Anderson1, Marion Haas, Marian Shanahan.   

Abstract

OBJECTIVE: To estimate the cost-effectiveness of altering the currently recommended interval and age range for cervical screening of Australian women.
METHODS: The cost and effectiveness estimates of alternative screening strategies were generated using an established decision model. This model incorporated a Markov model (of the natural history of cervical cancer and pre-cancerous lesions) and decision trees which: 'mapped' the various pathways to cervical cancer screening; the follow-up of abnormal Pap test results; and the management of confirmed lesions. The model simulated a hypothetical large cohort of Australian women from age 15 to age 85 and calculated the accumulated costs and life-years under each screening strategy.
RESULTS: Our model estimated that moving from the current two-yearly screening strategy to annual screening (over the same age range) would cost $379,300 per additional life-year saved. Moving from the current strategy to three-yearly screening would yield $117,100 of savings per life-year lost (costs and effects both discounted at 5% per year), with a relatively modest (<5%) reduction in the total number of life-years saved by the program.
CONCLUSIONS: Although moving to annual screening would save some additional lives, it is not a cost-effective strategy. Consideration should be given to increasing the recommended interval for cervical screening. However, the net value of any such shift to less effective (e.g. less frequent) and less costly screening strategies will require better evidence about the cost-effectiveness of strategies that encourage non-screeners or irregular screeners to have a Pap test more regularly.

Entities:  

Mesh:

Year:  2008        PMID: 18290913     DOI: 10.1111/j.1753-6405.2008.00165.x

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  6 in total

1.  Calibrating models in economic evaluation: a seven-step approach.

Authors:  Tazio Vanni; Jonathan Karnon; Jason Madan; Richard G White; W John Edmunds; Anna M Foss; Rosa Legood
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

2.  Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years.

Authors:  Prudence Creighton; Jie-Bin Lew; Mark Clements; Megan Smith; Kirsten Howard; Suzanne Dyer; Sarah Lord; Karen Canfell
Journal:  BMC Public Health       Date:  2010-11-26       Impact factor: 3.295

3.  Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.

Authors:  Michael P Pignone; Kathy L Flitcroft; Kirsten Howard; Lyndal J Trevena; Glenn P Salkeld; D James B St John
Journal:  Med J Aust       Date:  2011-02-21       Impact factor: 7.738

4.  Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information.

Authors:  James F O'Mahony; Joost van Rosmalen; Ann G Zauber; Marjolein van Ballegooijen
Journal:  Med Decis Making       Date:  2012-08-27       Impact factor: 2.583

5.  Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.

Authors:  I H-I Chow; C-H Tang; S-L You; C-H Liao; T-Y Chu; C-J Chen; C-A Chen; R-F Pwu
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

Review 6.  Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening.

Authors:  Juliana Yukari Kodaira Viscondi; Christine Grutzmann Faustino; Alessandro Gonçalves Campolina; Alexander Itria; Patricia Coelho de Soárez
Journal:  Clinics (Sao Paulo)       Date:  2018-07-10       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.